Overview
Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist developed by Eli Lilly that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This unprecedented triple agonism produced the highest weight loss ever recorded in an obesity clinical trial—up to 24.2% body weight reduction at 48 weeks in Phase 2.
The inclusion of glucagon receptor agonism sets retatrutide apart from existing therapies like semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual). Glucagon activation increases energy expenditure through hepatic lipid oxidation, thermogenesis, and enhanced metabolic rate—addressing the 'energy output' side of the equation while GLP-1 and GIP address 'energy input' through appetite suppression and improved insulin sensitivity.
Phase 2 trial results published in the New England Journal of Medicine in 2023 generated enormous scientific interest: at the highest dose (12 mg), mean body weight loss reached 24.2%, with some participants losing over 30% of their starting weight. These results approach the efficacy of bariatric surgery, a milestone for pharmacological obesity treatment.
Phase 3 trials (TRIUMPH program) are underway across multiple indications including obesity, type 2 diabetes, and MASLD/NASH. If efficacy and safety are confirmed at scale, retatrutide could represent a paradigm shift in metabolic disease treatment.
Quick facts
- Mechanism
- Triple GIP/GLP-1/glucagon receptor agonist for maximum metabolic impact
- Primary use
- Obesity & Metabolic Disease
- Evidence
- strong
- FDA
- Not approved
- Route
- Subcutaneous injection (once weekly)
- Typical results
- Up to 24.2% body weight loss at 48 weeks in Phase 2 trials
Chemical information
Retatrutide is a 39-amino acid peptide with a molecular mass of approximately 4,605 g/mol. It features a C20 fatty diacid moiety attached via a linker to enable albumin binding and extended half-life. The peptide sequence is engineered to provide balanced agonism across GIP, GLP-1, and glucagon receptors through strategic amino acid substitutions at key receptor-interaction positions.
How Retatrutide works
Retatrutide is a 39-amino acid peptide engineered to activate three distinct G-protein coupled receptors (GPCRs) involved in energy homeostasis and glucose metabolism. Its balanced agonism at GIP, GLP-1, and glucagon receptors creates a synergistic metabolic effect that exceeds what any single or dual agonist can achieve.
GLP-1 receptor activation drives appetite suppression through hypothalamic and brainstem satiety circuits, delays gastric emptying, and enhances glucose-dependent insulin secretion. GIP receptor agonism potentiates insulin secretion, improves adipose tissue metabolism, and may enhance the central anorectic effects of GLP-1. The combination of these two mechanisms forms the basis of tirzepatide's efficacy.
The addition of glucagon receptor agonism is the key differentiator. Glucagon traditionally viewed as a counter-regulatory hormone that raises blood glucose, also profoundly stimulates hepatic fatty acid oxidation, increases energy expenditure, and promotes thermogenesis. At the doses used in retatrutide, the hyperglycemic effect of glucagon is counterbalanced by GLP-1 and GIP-mediated insulin secretion, allowing the metabolic benefits of glucagon to manifest without significant glucose elevation.
Preclinical and clinical data suggest that the glucagon component contributes approximately 5–8 percentage points of additional weight loss beyond what GIP/GLP-1 dual agonism provides. This extra efficacy appears to come from increased resting energy expenditure (5–10% increase) and enhanced hepatic lipid clearance, which also benefits liver steatosis.
- GLP-1 agonism: Suppresses appetite, delays gastric emptying, enhances insulin secretion
- GIP agonism: Potentiates insulin response, improves adipose metabolism, enhances central satiety
- Glucagon agonism: Increases energy expenditure, promotes hepatic fat oxidation, thermogenesis
- Synergistic glucose control: GLP-1/GIP insulin effects counterbalance glucagon's hyperglycemic action
- MASLD/NASH benefit: Glucagon-driven hepatic lipid clearance reduces liver fat
- Energy expenditure boost: Glucagon component increases resting metabolic rate by 5–10%
Pharmacokinetics
Pharmacokinetic data from Phase 1 and Phase 2 clinical trials.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (SC) | ~70–80% (estimated) | Good absorption for once-weekly peptide |
| Half-life | ~6 days | Supports once-weekly dosing |
| Tmax | 24–60 hours | Gradual absorption from subcutaneous depot |
| Protein binding | >99% (albumin) | Fatty acid acylation enables extended duration |
| Steady state | 4–5 weeks | Achieved during dose escalation period |
| Metabolism | Proteolytic degradation | No significant CYP enzyme interactions expected |
Dosing & administration
In Phase 2 trials, retatrutide was studied at doses of 1, 4, 8, and 12 mg administered once weekly. The dose escalation schedule for the 12 mg dose followed: 2 mg × 4 weeks → 4 mg × 4 weeks → 8 mg × 4 weeks → 12 mg maintenance. This gradual titration was essential for GI tolerability.
The 12 mg dose produced the maximum weight loss (24.2% at 48 weeks), but the 8 mg dose also showed impressive efficacy (22.8%) with potentially better tolerability. The optimal dose for Phase 3 is expected to be 8–12 mg weekly.
Retatrutide is not yet commercially available. Phase 3 trials are ongoing, and dosing recommendations will be finalized upon regulatory review. The medication is administered as a once-weekly subcutaneous injection.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
In Phase 2 trials, retatrutide demonstrated an acceptable safety profile consistent with the incretin drug class. GI side effects were the most common but were mostly mild to moderate and improved with continued treatment and dose escalation. No unexpected safety signals emerged from the triple agonist mechanism. Phase 3 trials with larger populations will provide more comprehensive safety data.
Common
- • Nausea (dose-dependent, 16–45%)
- • Diarrhea (14–25%)
- • Vomiting (9–22%)
- • Constipation
- • Decreased appetite (therapeutic effect)
- • Injection site reactions
Serious / potential risks
- • Severe GI events requiring dose adjustment or discontinuation
- • Increased heart rate (4–8 bpm increase observed)
- • Pancreatitis monitoring required (incretin class)
- • Gallbladder events with rapid weight loss
- • Theoretical thyroid C-cell risk (GLP-1 class warning)
Drug interactions
Limited drug interaction data; based on pharmacological mechanism and incretin class experience.
| Medication | Interaction | Recommendation |
|---|---|---|
| Insulin | Significant hypoglycemia risk from triple-pathway glucose lowering | Reduce insulin dose by 30–50% when initiating |
| Sulfonylureas | Additive hypoglycemia risk | Consider dose reduction or discontinuation |
| Oral contraceptives | Delayed gastric emptying may reduce absorption | Consider alternative contraception or timing adjustments |
| Levothyroxine | Absorption may be affected by delayed gastric emptying | Take on empty stomach; monitor TSH more frequently |
| Warfarin | Potential absorption changes during dose escalation | Monitor INR closely during initiation period |
Storage & handling
Pre-filled Pen (Expected)
- • Expected refrigerated storage (2–8°C) before first use
- • Room temperature stability for in-use period
- • Protect from direct light and freezing
- • Single-patient use; do not share between patients
Multi-dose Pen (Expected)
- • Dose escalation pen format likely for titration period
- • Attach new needle for each injection
- • Follow pen-specific storage instructions once available
- • Discard used needles in sharps container
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Clinical trials | Not yet available | Phase 3 TRIUMPH trials ongoing |
| Projected pricing | $800–$1,500/month (estimated) | Expected to be competitive with tirzepatide |
| Comparison: Mounjaro | $1,023/month (list) | Retatrutide may offer superior efficacy at similar price point |
The bottom line
Retatrutide is a metabolic compound with research interest in weight loss, triple agonist, metabolic syndrome, nafld. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in weight loss under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med (2023). doi: 10.1056/NEJMoa2301972 PMID: 37351564
- [2] Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. Lancet (2023). doi: 10.1016/S0140-6736(23)01053-X PMID: 37385280
- [3] Finan B, Yang B, Ottaway N, et al.. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med (2015). doi: 10.1038/nm.3761 PMID: 25362455
- [4] Day JW, Ottaway N, Patterson JT, et al.. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009). doi: 10.1038/nchembio.209 PMID: 19915529
- [5] Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab (2022). doi: 10.1016/j.cmet.2022.07.013 PMID: 35985340